Relapse-free cure from multidrug-resistant tuberculosis in Germany.
Jan Heyckendorf 
;
Frank van Leth;
Barbara Kalsdorf;
Ioana D Olaru ;
Gunar Günther;
Helmut JF Salzer;
Elena Terhalle;
Thierry Rolling;
Georg Glattki;
Marius Müller;
+3 more...
Maren Schuhmann;
Korkut Avsar;
Christoph Lange;
(2018)
Relapse-free cure from multidrug-resistant tuberculosis in Germany.
The European respiratory journal, 51 (2).
p. 1702122.
ISSN 0903-1936
DOI: 10.1183/13993003.02122-2017
;
Frank van Leth;
Barbara Kalsdorf;
Ioana D Olaru ;
Gunar Günther;
Helmut JF Salzer;
Elena Terhalle;
Thierry Rolling;
Georg Glattki;
Marius Müller;
+3 more...
Maren Schuhmann;
Korkut Avsar;
Christoph Lange;
(2018)
Relapse-free cure from multidrug-resistant tuberculosis in Germany.
The European respiratory journal, 51 (2).
p. 1702122.
ISSN 0903-1936
DOI: 10.1183/13993003.02122-2017
Multidrug-resistant (MDR) tuberculosis (TB), defined by bacillary resistance against rifampicin and isoniazid, has been identified as a global threat to mankind [1]. According to the latest report by the European Centres for Disease Prevention and Control, and World Health Organization (WHO) regional office for Europe, only approximately 50% of MDR-TB patients in Europe reach favourable treatment outcomes [2]. Successful treatment outcomes are achieved for less than 25% of patients with extensively drug-resistant (XDR)-TB (MDR plus resistance against a least one fluoroquinolone and one second-line injectable drug) in the European Union/European Economic Area Countries [2].
-
picture_as_pdf - Heyckendorf et al ERJ RL R1 MARKED 24112017 for archive.pdf
-
subject - Accepted Version
-
- Available under Creative Commons: NC-ND 3.0
Downloads